Hong Kong Stock News

Amidst global economic fluctuations and geopolitical tensions, Asian markets have been navigating a complex landscape marked by mixed signals from trade data and inflationary pressures. As investors seek opportunities within this environment, identifying undervalued stocks becomes crucial, especially those trading below their intrinsic value, offering potential for growth despite prevailing uncertainties.

As global markets navigate a complex landscape of geopolitical tensions and economic shifts, Asia's financial scene remains a focal point for investors seeking growth opportunities. Despite the challenges, penny stocks in this region continue to attract attention due to their affordability and potential for significant returns. Often representing smaller or emerging companies, these stocks can offer compelling investment opportunities when they demonstrate strong financial health and growth...

Dividend approval and audit reappointment set the stage for China Foods China Foods (SEHK:506) drew investor attention after its 9 June 2026 AGM, where shareholders approved a final ordinary dividend of RMB 0.154 per share and reappointed Baker Tilly Hong Kong Limited as auditor. See our latest analysis for China Foods. At a share price of HK$3.46, China Foods has seen its 1 year total shareholder return of 17.51% contrast with a weaker year to date share price return of a 19.53% decline,...

Cathay Pacific Airways has announced that Chief Financial Officer and Executive Director Rebecca Jane Sharpe will retire from the Swire group on 1 October 2026, to be succeeded by Gavin John March, currently finance director at Swire Bulk Holdings. The planned handover to March, who brings aviation, engineering and shipping finance experience from across the Swire group, reshapes the airline’s senior financial leadership profile. We’ll now examine how this planned CFO transition to Gavin...

Clinical trial approval for TUL321 puts United Laboratories in focus United Laboratories International Holdings (SEHK:3933) has received approval from China's National Medical Products Administration to begin clinical trials for TUL321, an autoimmune drug that already holds U.S. FDA Investigational New Drug clearance. See our latest analysis for United Laboratories International Holdings. Those clinical trial and buyback announcements come after a tough spell for the stock. The 1-year total...

Board changes put governance and oversight in focus China Literature (SEHK:772) used its 2 June annual general meeting to reshuffle its independent board lineup, introduce fresh expertise in law and accounting, and approve updated constitutional documents. For investors, these moves raise practical questions about how audit quality, risk oversight, and intellectual property decisions might be handled over the coming years, especially given the company’s role within Tencent’s broader content...

In May 2026, Longfor Group Holdings reported unaudited contracted sales of RMB3.32 billion for the month and RMB13.67 billion for the first five months, alongside RMB11.14 billion of aggregated revenue from property operation and services and the acquisition of a new 76,985 sqm land plot for RMB374 million. Morgan Stanley highlighted Longfor Group’s proactive de-stocking approach and improving mall rental performance as key elements in its ongoing balance sheet risk reduction efforts. We’ll...

Ascentage Pharma Group International (SEHK:6855) drew fresh market attention after presenting new ASCO 2026 data on olverembatinib in chronic myeloid leukemia and first clinical results for alrizomadlin in pediatric sarcomas. See our latest analysis for Ascentage Pharma Group International. The ASCO 2026 updates arrived as the stock posted a 3.93% 1 day share price gain to HK$34.9. That move sits against a year to date share price decline of 31.43% and a 1 year total shareholder return that...

XtalPi Holdings (SEHK:2228) has entered a new partnership with a major international biopharma company to develop oral small molecule drugs targeting a complex GPCR. The collaboration uses XtalPi's AI and quantum physics platforms, combined with automated labs, to work on challenging GPCR targets. The deal carries a potential value of more than US$400 million, reflecting meaningful commercial scope for XtalPi's technology. XtalPi Holdings trades at HK$7.04, with the share price down 6.0%...

Majestic Dragon AeroTech Holdings (SEHK:918) has released fresh numbers for FY 2026, with first half revenue of HK$75.8 million and basic EPS of HK$0.005443 setting the tone for how you might read the rest of the year. The company reported revenue of HK$18.1 million in the first half of FY 2025 and HK$100.6 million in the second half of FY 2025, with EPS shifting from a loss of HK$0.014725 to a loss of HK$0.00439. The latest positive EPS print therefore sits against a mixed recent history...

Shareholders of Chow Tai Fook Jewellery Group Limited ( HKG:1929 ) will be pleased this week, given that the stock...

Prada (SEHK:1913) has attracted fresh attention after unveiling an inner-layer garment for NASA astronauts, created with Axiom Space. This signals a push beyond traditional luxury products into space-related apparel. See our latest analysis for Prada. The HK$40.58 share price has been supported by short term momentum, with a 1 day share price return of 3.79% and a 7 day share price return of 10.45%. However, the 1 year total shareholder return is down 9.83%, pointing to a stock still...

Sunny Optical Technology (Group) (SEHK:2382) has been removed from the Hang Seng China Enterprises Index. This change can affect index-tracking flows and how some institutional investors view the stock. See our latest analysis for Sunny Optical Technology (Group). The index removal comes after a sharp 12.8% decline in the 7 day share price return, even though the 30 day and 90 day share price returns of 8.74% and 26.86% point to recovering momentum from a HK$71.55 base. This compares with a 1...

BYD Electronic (International) Company Limited announced at its 9 June 2026 AGM that it approved a 2025 final dividend of RMB 0.156 per share and confirmed board changes, including the retirement of two independent non-executive directors. The appointment of industry veteran Ms. Rong Xiu-li and accounting expert Professor Mr. Cao Yu-shan to lead key board committees materially reshapes the company’s governance profile. We will now examine how these refreshed independent appointments,...

If you are trying to figure out whether WuXi Biologics (Cayman) is attractively priced or not, a useful starting point is to separate short term share price noise from the company’s underlying value. The stock last closed at HK$31.08. The share price is up 11.0% over the past year but down 5.1% over the past week, 8.2% over the past month and 34.5% over three years, while the five year return is down 76.5%. Recent headlines around WuXi Biologics (Cayman) have focused on broader sector...

Potential Ruichang International Holdings Limited ( HKG:1334 ) shareholders may wish to note that the CEO, Interim...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Viewing insider transactions for Ascletis Pharma Inc.'s ( HKG:1672 ) over the last year, we see that insiders were net...

Readers hoping to buy Wing On Company International Limited ( HKG:289 ) for its dividend will need to make their move...

Dividend approval puts Uni-President China Holdings (SEHK:220) in focus Uni-President China Holdings (SEHK:220) has drawn investor attention after its annual general meeting approved a final dividend of 47.47 RMB cents per share for the 2025 financial year. The payout goes to shareholders on the register as of 15 June 2026. Dividend cheques are expected to be mailed on or around 8 July 2026, providing investors with clearer information on upcoming cash returns. See our latest analysis for...

Prada (SEHK:1913) has partnered with Axiom Space to design astronaut garments for NASA's upcoming lunar missions. The luxury group will focus on inner-layer garments for future moon missions, extending its design expertise into space-focused technical wear. For investors tracking Prada at a current share price of HK$40.58, this move sits alongside a mixed return profile. The stock is up 10.5% over the past week and 13.0% over the past month, while returns over the past year and longer...

HSBC’s latest Asia emerging markets report has put China Resources Land (SEHK:1109) on investors’ radar after highlighting expected margin improvement and upcoming flagship launches in Shanghai and Shenzhen. See our latest analysis for China Resources Land. At a share price of HK$37.28, China Resources Land has seen short term momentum cool slightly with a 1 month share price return that declined 2.41%. However, the 90 day share price return of 23.94% and 1 year total shareholder return of...

Fresh from releasing its FY 2026 numbers, Eagle Nice (International) Holdings (SEHK:2368) reported first half revenue of HK$3.3 billion and basic EPS of HK$0.36, with trailing twelve month revenue at HK$5.1 billion and basic EPS at HK$0.30. Over the past three reported half year periods, revenue has moved from HK$3.0 billion in 1H FY 2025 to HK$1.8 billion in 2H FY 2025 and HK$3.3 billion in 1H FY 2026, while basic EPS shifted from HK$0.33 to HK$0.06 and then HK$0.36, setting up a mixed...

In June, Everest Medicines (SEHK:1952) signed a global out licensing deal with Travere Therapeutics for its BTK inhibitor civorebrutinib (EVER001). The company also agreed to acquire presbyopia therapy LNZ100 from Corxel Pharmaceuticals and secured a regional cardiovascular licensing partnership for Sumecigrel from Jiangsu Vcare PharmaTech. Together, these transactions expand Everest Medicines' pipeline in nephrology, ophthalmology and cardiovascular disease while widening its collaboration...